FDA Actions against Misleading or Unsubstantiated Economic and Quality-of-Life Promotional Claims: An Analysis of Warning Letters and Notices of Violation
- 1 September 2002
- journal article
- Published by Elsevier in Value in Health
- Vol. 5 (5) , 390-397
- https://doi.org/10.1046/j.1524-4733.2002.55146.x
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Regulatory Issues for Health-Related Quality of Life— PhRMA Health Outcomes Committee Workshop, 1999Value in Health, 2002
- Michael Oakeshott, ou comment repenser le conservatisme ?Cités, 2001
- QL4: QUALITY OF LIFE MESSAGES IN PRESCRIPTION DRUG ADVERTISEMENTS IN LEADING MEDICAL JOURNALS, 1990-99Value in Health, 2001
- US Regulation of Pharmaceutical Outcomes Research Presented at the ISPOR 5th Annual International Meeting, Crystal City, VA, 24 May 2000Value in Health, 2001
- The FDA's regulation of health economic information.Health Affairs, 2000